Login to Your Account

UK Firm Spirogen Focuses On DNA-Targeted Therapies

By Karen Pihl-Carey

Wednesday, January 3, 2007
Nearly three years after moving its first agent into Phase I trials, Spirogen Ltd. is starting off 2007 with similar plans for a second compound. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription